 ADC Therapeutics S.A. shares rocketed 56 Friday in their trading debut, after the Swiss biotechs initial public offering priced above its proposed price range and underwriters increased the size of the deal. The company sold 12.2 million shares priced at 19 each, above the price range of 16 to 18, to raise 233 million with proceeds to be used to fund clinical research. The stock is trading on the NYSE under the ticker symbol ADCT. Morgan Stanley, BofA Securities and Cowen were the lead underwriters on the deal. The company recorded a net loss of 116.5 million on contract revenue of 2.3 million in 2019, compared with a loss of 123.1 million on revenue of 1.1 million in 2018. 